ELI LILLY & Co (LLY) stock price, news and key stats

Price

Last trade as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$1,136.71

Open

$1,137.22

Day range

$1,132.74 – $1,151.19

Volume

66.9K

52-week range

$712.05 – $1,292.65

Market cap

$1.0T

Forward P/E

24.0

Dividend yield

61.00%

Beta

0.50

Avg. volume

2.7M

Analyst target

$1,324.87

Next earnings

Oct 29, 2026

About ELI LILLY & Co

Latest LLY news

• Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
  CNBC · Sep 15, 2026

  Wells Fargo has reported an improvement in its net interest income, a key metric that reflects the bank's ability to generate revenue from its lending activities. The increase comes amid a rising interest rate environment, which has allowed financial institutions to benefit from higher loan yields. Analysts view this uptick as a positive sign for Wells Fargo's overall profitability, suggesting that the bank may be better positioned to navigate economic uncertainties and enhance shareholder value. In a separate development, Eli Lilly has garnered attention for its broader portfolio beyond its GLP-1 diabetes and weight-loss drugs. The pharmaceutical giant's recent advancements in other therapeutic areas, particularly in oncology and neurodegenerative diseases, have led to increased investor confidence. This diversification strategy may bolster Lilly's market position and mitigate risks associated with dependence on a single product line. As both companies navigate their respective sectors, investors are likely to keep a close eye on their performance metrics and strategic initiatives, which could influence market trends in the financial and healthcare sectors.

• Lilly’s Foundayo Quickly Gains Ground in the Oral Weight-Loss Market
  Yahoo Finance · Sep 15, 2026

  Eli Lilly's newly launched oral obesity drug, Foundayo, has quickly captured over 30% of the U.S. market for new patients starting oral weight-loss medications, marking a significant early achievement in a competitive landscape dominated by Novo Nordisk. This rapid uptake underscores the growing demand for effective weight management solutions as obesity rates continue to rise. Foundayo's performance is particularly noteworthy given the increasing scrutiny and competition in the obesity treatment sector, where innovative therapies are becoming more prevalent. The recent approval of Foundayo in the U.K. further enhances its market position, as it becomes Europe's second GLP-1 weight-loss pill and the first to be authorized for both weight management and type 2 diabetes. This dual indication could broaden its appeal and usage among healthcare providers and patients alike. As Foundayo rolls out, it will initially be available through private prescriptions, with expectations of future availability through the National Health Service (NHS), which could significantly expand its patient base. Market analysts are closely monitoring the implications of Foundayo's early success on Eli Lilly's overall performance and its competitive stance against Novo Nordisk. The promising sales figures reported for Q2 2026 suggest that Eli Lilly is well-positioned to challenge its rival, potentially reshaping market dynamics in the oral weight-loss segment. As both companies continue to innovate, the evolving landscape may lead to increased investment in obesity treatments, benefiting patients and healthcare systems.

• Novo Nordisk (NVO)’s Pediatric Obesity Opportunity Faces a Bigger Test
  Yahoo Finance · Sep 12, 2026

  Novo Nordisk A/S has reported promising results from its STEP Young Phase 3 clinical trial, which assessed the efficacy of once-weekly semaglutide in treating obesity in children aged 6 to under 12. The trial revealed that 40.4% of participants achieved a significant reduction in body weight, raising hopes for the drug's potential in pediatric obesity management. This development comes at a crucial time as the competitive landscape for GLP-1 weight-loss therapies intensifies, particularly with rival Eli Lilly gaining ground in the market. Despite the positive data, Novo Nordisk faces a challenging environment as it seeks to regain market share lost to Eli Lilly in recent years. The success of semaglutide in younger populations could bolster the company's position, but it will need to navigate hurdles such as regulatory approvals and public acceptance of obesity treatments for children. Market analysts will be closely monitoring how these factors influence Novo Nordisk's stock performance and overall strategy in the increasingly competitive obesity treatment sector. As the pediatric obesity epidemic continues to grow, the implications of this trial could extend beyond Novo Nordisk, potentially reshaping treatment approaches across the industry.

• The benefits of next-generation peptides will be thinly spread
  FT Companies · Sep 9, 2026

  Next-generation peptides, which have garnered attention for their potential in various therapeutic applications, are likely to face challenges in widespread adoption due to their cost and consumer price sensitivity. A recent survey indicates that pricing is a significant factor influencing consumer decisions, with many opting to discontinue use when faced with rising costs. This trend suggests that while the scientific advancements in peptide technology may be promising, their market penetration could be limited if manufacturers do not address affordability. The implications for the peptide market are considerable. As companies strive to innovate and differentiate their products, they may need to balance the costs of research and development with the price points that consumers are willing to accept. If manufacturers cannot find a way to produce these next-generation peptides at a lower cost, the benefits of their advancements may be "thinly spread" across a limited consumer base. This could lead to a fragmented market where only a few players succeed, while others struggle to maintain profitability in a price-sensitive environment. Investors and stakeholders should monitor how pricing strategies evolve in response to consumer behavior, as this will be crucial for the future of peptide therapeutics.

• Lilly perseveres in a bad day for drug stocks — plus, Boeing's mixed deliveries
  CNBC · Sep 8, 2026

  Eli Lilly & Co. demonstrated resilience amid a challenging day for the pharmaceutical sector, as broader market concerns weighed on drug stocks. Despite a downturn affecting many in the industry, Lilly's shares remained relatively stable, buoyed by strong fundamentals and positive investor sentiment surrounding its pipeline of innovative treatments. Analysts suggest that Lilly's focus on diabetes and obesity drugs, particularly its weight-loss medication, continues to attract interest, potentially shielding it from the broader market volatility. In contrast, Boeing Co. reported mixed delivery figures that raised eyebrows among investors. The aerospace giant delivered 35 commercial airplanes in September, a slight increase from the previous month, but fell short of market expectations. This discrepancy has led to concerns about Boeing's recovery trajectory amid ongoing supply chain challenges and production delays. As the company navigates these hurdles, its stock performance may remain under pressure, impacting investor confidence in the aerospace sector as a whole. The mixed results highlight the ongoing volatility in both the pharmaceutical and aerospace industries, suggesting that investors should remain cautious as they assess the broader market landscape.

• Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff
  MarketWatch · Sep 8, 2026

  Shares of Novartis plummeted over 3% on Monday following the disappointing results of a pivotal trial for its cholesterol drug, which aimed to lower lipoprotein(a) or Lp(a) levels to reduce cardiovascular risks. The failure of this trial not only undermines Novartis's strategy but also raises concerns about the broader viability of Lp(a) targeting therapies in the biopharmaceutical sector. Investors had anticipated significant advancements in this area, making the trial results particularly impactful. The fallout from Novartis's announcement extended beyond its own stock, triggering a selloff across the biopharma industry as market participants reevaluated the potential of similar treatments from other companies. The collective market response reflects a growing skepticism towards the efficacy of Lp(a) lowering strategies, which had garnered considerable attention and investment. Analysts suggest that this could lead to a reevaluation of research and development priorities within the sector, as companies may now face increased pressure to demonstrate the viability of their cardiovascular drug pipelines.

• Cholesterol drug setback casts doubt over multibillion-dollar race
  CNBC Top News · Sep 8, 2026

  Novartis' recent setback in its cholesterol drug development has intensified competition among pharmaceutical giants Amgen and Eli Lilly, both of which are racing to deliver therapies aimed at lowering lipoprotein(a) or Lp(a) levels. The failure of Novartis' treatment not only raises questions about the viability of similar approaches but also underscores the high stakes involved in this multibillion-dollar market. Investors are now closely monitoring the progress of Amgen and Eli Lilly, as successful outcomes could lead to significant market share and revenue growth in a sector that is increasingly focused on cardiovascular health. The implications of Novartis' failure extend beyond the immediate competitors. The setback may lead to increased scrutiny of clinical trial designs and efficacy standards for cholesterol-lowering drugs, potentially delaying the approval of new treatments. Market analysts suggest that the disappointment could dampen investor sentiment in the sector, particularly for companies with similar drug candidates in development. As Amgen and Eli Lilly advance their trials, the pressure to deliver effective results will be paramount, not only to capture market share but also to restore confidence in the therapeutic approach to managing Lp(a) levels and reducing cardiovascular events.

• Trump's tariffs have cost Indiana over $8 billion
  Macro Watch · Sep 4, 2026

  According to a recent report by Macro Watch, tariffs implemented during Donald Trump's presidency have resulted in an estimated cost of over $8 billion to the state of Indiana. This figure, derived from data provided by Trade Partnership Worldwide and analyzed by the National Taxpayers Union Foundation, highlights the significant economic impact of trade policies on local economies, particularly in manufacturing-heavy states like Indiana. The tariffs, which were primarily aimed at China and other trading partners, have led to increased costs for businesses reliant on imported goods, ultimately passing these expenses onto consumers. As a result, Indiana's economy, which is heavily reliant on sectors such as automotive and agriculture, has faced challenges in maintaining competitiveness. The report suggests that these tariffs could continue to affect the state’s economic landscape through June 2026, as businesses adapt to ongoing trade uncertainties. Market implications are significant, as the financial burden of tariffs may hinder growth prospects for Indiana's industries, potentially leading to job losses and reduced investment. As policymakers and businesses navigate these challenges, the long-term effects of such trade measures will likely remain a critical topic in discussions surrounding economic recovery and growth strategies in the region.

• Global pharma companies that have publicly announced Trump drug pricing agreements
  Forex News · Sep 1, 2026

  The Trump administration has secured drug pricing agreements with a total of 26 pharmaceutical companies, aiming to significantly reduce prescription costs for American consumers. The latest round of deals, announced recently, includes nine additional companies, bringing the total to cover 89% of brand-name drugs. This initiative is part of a broader strategy to address the high costs of medications, which can be nearly three times higher in the U.S. compared to other countries. Major pharmaceutical firms involved in these agreements include industry giants such as Pfizer, Eli Lilly, and Amgen. The administration's approach, which emphasizes a "most-favored-nation" pricing model, seeks to align U.S. drug prices with those in other countries, potentially reshaping the market landscape. As these agreements take effect, they may lead to increased scrutiny of drug pricing practices and could pressure other companies to follow suit or face public backlash. Market implications of these agreements could be significant. Investors may react to the potential for reduced profit margins in the pharmaceutical sector, while consumers could benefit from lower out-of-pocket costs for medications. Additionally, the agreements may influence the ongoing discussions around healthcare reform in the U.S., as both political and public sentiment increasingly favors measures that promote affordability in healthcare.

• Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future
  NYT Business · Sep 1, 2026

  Novo Nordisk's recent struggles have raised concerns among investors, particularly following the disappointing results of its late-stage experimental drug, CagriSema. The company announced that the drug failed to meet its clinical trial endpoints, leading to a significant drop in its stock price, which fell by nearly 10% on Friday, erasing over $30 billion in market capitalization. This setback has prompted criticism from investors who feel misled about the drug's tolerability and potential. CEO Mike Doustdar, who is in the midst of a corporate turnaround, asserts that the long-term potential of Novo Nordisk's drug pipeline remains underestimated. However, with increasing competition from rivals like Eli Lilly, which has also seen its weight loss drug stocks decline, Wall Street is expressing skepticism about Novo Nordisk's ability to regain a sustainable growth trajectory. The market's reaction reflects a broader concern about the viability of the obesity treatment sector, particularly as investors brace for upcoming earnings reports that may further clarify the company's outlook. As the pharmaceutical landscape evolves, Novo Nordisk's future hinges on its ability to navigate these challenges and restore investor confidence. The company must demonstrate that its remaining products can deliver on their promises, especially in a market where competition is intensifying and investor sentiment is fragile.

All 43 articles in the app →

Earnings history

Index membership

• S&P 500 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BIIBBiogen